Program Status
Active, not recruitingPhase
Phase 1 Phase 2Prior Immunotherapy Allowed
NoCRC-directed Trial
YesDrugs
ELI-002 7PTags
MSI-H/ MMRd, MSS/ MMRpComments
KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor.
For patients with positive for circulating tumor DNA and/or elevated serum tumor biomarkers (such as CA19-9 and CEA) despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable.
Patients must be NED.
Vaccine trial to prevent recurrence.
Helpful Links
https://elicio.com/wp-content/uploads/2024/11/2024-SITC-poster-FINAL.pdf https://aacrjournals.org/cancerres/article/84/7_Supplement/CT107/742482 https://www.nature.com/articles/s41591-023-02760-3| Location | Location Status |
|---|---|
| United States | |
|
Banner MD Anderson Cancer Center Gilbert, Arizona 85234 |
Active, not recruiting |
|
Mayo Clinic Comprehensive Cancer Center Phoenix, Arizona 85054 |
Active, not recruiting |
|
City of Hope Duarte, California 91010 |
Active, not recruiting |
|
Cedars-Sinai Medical Center Los Angeles, California 90048 |
Active, not recruiting |
|
University of California Los Angeles Los Angeles, California 90095 |
Active, not recruiting |
|
University of California, Irvine Orange, California 92868 |
Active, not recruiting |
|
University of Colorado Hospital-Anschutz Cancer Pavillion Aurora, Colorado 80045 |
Active, not recruiting |
|
University of Miami Coral Gables, Florida 33124 |
Active, not recruiting |
|
University of Florida Health Cancer Center Gainesville, Florida 32610 |
Active, not recruiting |
|
Mayo Clinic Comprehensive Cancer Center Jacksonville, Florida 32224 |
Active, not recruiting |
|
Moffitt Cancer Center Tampa, Florida 33612 |
Active, not recruiting |
|
Emory Winship Cancer Institute Atlanta, Georgia 30322 |
Active, not recruiting |
|
University of Iowa Iowa City, Iowa 52242 |
Active, not recruiting |
|
Ochsner Health New Orleans, Louisiana 70121 |
Active, not recruiting |
|
Massachusetts General Hospital Boston, Massachusetts 02210 |
Active, not recruiting |
|
Dana Farber Cancer Institute Boston, Massachusetts 02215 |
Active, not recruiting |
|
University of Michigan Ann Arbor, Michigan 48109 |
Active, not recruiting |
|
Mayo Clinic Comprehensive Cancer Center Rochester, Minnesota 55905 |
Active, not recruiting |
|
Northwell Health Lake Success, New York 11042 |
Active, not recruiting |
|
Memorial Sloan Kettering Cancer Center New York, New York 10022 |
Active, not recruiting |
|
New York Presbyterian Weill Cornell Medical Center New York, New York 10065 |
Active, not recruiting |
|
Lehigh Valley Health Network Allentown, Pennsylvania 18003 |
Active, not recruiting |
|
University of Pennsylvania Philadelphia, Pennsylvania 19104 |
Active, not recruiting |
|
Sarah Cannon Research Institute Nashville, Tennessee 37203 |
Active, not recruiting |
|
Vanderbilt University Medical Center Nashville, Tennessee 37212 |
Active, not recruiting |
|
University of Texas Southwestern Dallas, Texas 75390 |
Active, not recruiting |
|
The University of Texas MD Anderson Cancer Center Houston, Texas 77030 |
Active, not recruiting |
|
Medical College of Wisconsin Milwaukee, Wisconsin 53226 |
Active, not recruiting |
Inclusion Criteria
Inclusion Criteria:
* KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor
* Phase 1 only: positive for circulating tumor DNA and/or elevated serum tumor biomarkers (such as CA19-9 and CEA) despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable
* Screening CT is negative for recurrent disease
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria
Exclusion Criteria:
* Presence of tumor mutations where specific therapy is approved
* Known brain metastases
* Use of immunosuppressive drugs
